Unlike cDC1, which activates CD8+ T cells through cross-presentation, ISG+ DC is able to acquire and present an intact tumor-derived peptide-MHC I complex and has the ability to activate CD8+ T cells in a manner comparable to cDC1, as well as promote protective anti-tumor immunity in the absence of cDC1. The gene discussed is CD8A; the disease is neoplasm.